Theravance Biopharma Announces Positive Results From NS5A Inhibitor Hepatitis C Drug Phase 1 Proof-of-Concept Study
Hepatitis C, News
Theravance Biopharma, through its U.S. operating subsidiary, South San Francisco, California-based Theravance Biopharma US, Inc., on Tuesday announced positive results from the first three cohorts of Study 0110 — a ... Read more